NRx Pharmaceuticals Reports First Quarter 2023 Financial Results, Provides Business Update

NRx Pharmaceuticals

RADNOR, PA NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) announced its financial results for the first quarter of 2023 and provided a business update.

“In the U.S. alone, nearly one million people suffer from Suicidal Treatment-Resistant Bipolar Depression, a lethal condition that ultimately leads to a suicide attempt in half of this patient population. Currently, there is no approved medicine for patients with this condition, and the only FDA-approved treatment is electroshock therapy, which has numerous known side-effects,” said Stephen Willard, J.D., Chief Executive Officer and Director of NRx Pharmaceuticals. “We are committed to demonstrating the therapeutic benefit of NRX-101, the first oral NMDA-targeted medicine to be developed for patients with suicidal bipolar depression, for these patients facing significant unmet need, and we remain on track to report initial data from this integrated trial in the fourth quarter of this year. We look forward to working with the U.S. FDA on the upgraded Phase 2b/3 trial of NRX-101 in the broader indication of Suicidal Treatment-Resistant Bipolar Depression during a Breakthrough Therapy Designation meeting later this quarter.”

First Quarter Clinical and Regulatory Highlights

NRX Pharma is engaged in the development of NRX-101, a fixed dose combination of D-cycloserine and lurasidone for the treatment of suicidal bipolar depression and potentially for other future indications. NRX-101 has been granted Fast Track Designation, Breakthrough Therapy Designation, a Special Protocol Agreement, and a Biomarker Letter of Support by the US Food and Drug Administration (FDA). In Q1 2023 the Company met with the FDA and was guided to expand its intended use of NRX-101 from the original population of patients with acute suicidality who might be treated in the hospital environment to the broader population of patients with subacute suicidal ideation (now described by the Company as Treatment-Resistant Bipolar Depression) who are treated in the outpatient setting. These patients are the current target population of the ongoing clinical trial.

Based on the guidance of FDA and the Company’s completion of manufacturing for phase 3/commercial stage investigational product, the Company upgraded the ongoing clinical trial to a phase 2b/3 trial, the results of which have the potential to be used for registrational filings. The Company is engaged in that ongoing clinical trial of NRX-101 vs. lurasidone in patients with treatment-resistant bipolar depression with the objective of demonstrating a decreased in depression scores and scores of suicidal ideation in patients treated with NRX-101 compared to those treated with lurasidone alone.

READ:  TELA Bio Stands Tall With Consistent Growth, Novel Products, and a Promising Revenue Projection for 2024

The clinical trial was originally begun as an exploratory study in Q2 2022, as disclosed in prior filings. In Q1 2023 the study’s independent Data Safety Monitoring Board (DSMB) reviewed both safety and unblinded efficacy data for the first 50 patients in the clinical trial and advised the Company that no safety concerns were identified. Moreover, the DSMB did not identify a futility signal, suggesting that the trial has potential to demonstrate a statistically significant outcome with additional enrollment. On this basis, the DSMB advised management to continue enrolling study participants.

During the first quarter of 2023, the Company refined its ability to validate the psychometric ratings that are used to assess the efficacy endpoints for the clinical trial. The Company relies upon a team of veteran raters who both train independent site rates and monitor the technical quality of each rating. A standard was set of 90% or better concordance between the Company’s veteran rating team and site raters. This standard was met for all study participants whose ratings were obtained in their primary language and management believes that this standard can be maintained for the duration of the trial.

In April 2023, the Company contracted with 1nHealth to initiate a recruitment campaign that may cover up to 45 states in the US to recruit sufficient participants for this enlarged trial. The Company has similarly broadened its previously disclosed relationship with Science 37, a contract research organization that conducts decentralized clinical trials, to enroll participants identified by the 1nHealth recruitment initiative and randomize them to be treated within the broadened clinical trial. 1nHealth has additionally engaged a voice-of-the-patient organization with national reach to publicize the clinical trial to the 400,000+ subscribers who have indicated a focus on bipolar depression and suicidality.

READ:  NovaData Solutions Secures Series A Funding to Revolutionize Property Restoration Billing with AI

In Q1 2023, the Company announced the participation of Prof. Andrew Nierenberg, M.D., Head of the Massachusetts General Hospital (MGH) Dauton Family Center for Bipolar Treatment Innovation as the Principal Investigator of the clinical trial. The Company has now initiated clinical trial sites at Northwestern University (Chicago) and University of Texas, Austin, in addition to commercial research sites.

NRX-101 Indication – Post Traumatic Stress Disorder (PTSD)

  • NRx plans to investigate NRX-101 in PTSD as an additional indication. The Company expects to commence planning for a Phase 2 clinical trial in the second quarter of 2023 with the study expected to be open for enrollment in 2023.
  • Depression in PTSD may be driven by pathways that are similar to those that drive depression in other conditions (NMDA and 5-HT2A). Additionally, approximately 10% of patients with PTSD may experience suicidality, especially those with severe PTSD.
  • In a preclinical PTSD study, D-cycloserine, a component of NRX-101, demonstrated the ability to extinguish recurring images of traumatic events, also known as fear memory, in a validated WKY model of PTSD. Ketamine has demonstrated an effect on this debilitating symptom of PTSD. Should NRX-101 have a similar beneficial effect, it has the potential to be the first labeled medicine for PTSD symptoms.

First Quarter Corporate Updates

  • In February 2023, the Company received notice of the issuance of a U.S. patent covering the lead formulation, NRX-101, a glycine site NMDA antagonist in clinical trials to treat bipolar depression with acute and subacute suicidality. This new patent covers the use of NRX-101 to treat patients suffering from depression, including bipolar depression or major depression (MDD) with or without suicidality and strengthens the Company’s intellectual property position until at least 2033.
  • In March 2023, the Company announced the close of a $2.9 million registered direct offering. Participants were existing investors, and the Company anticipates using the proceeds to initiate its national treatment protocol and safety database for NRX-101 for treatment-resistant bipolar depression with risk of self-harm under an FDA expanded access protocol, and to advance its pipeline of life-saving therapeutics.
  • The Company has continued to engage in a strategic conversation focused on funding the drug approval and commercialization. In parallel, the Company has established an ongoing dialogue with Streeterville Capital LLC, the Company’s current debt lender, to modify the Company’s current debt facility to best support the ongoing needs of the clinical trial.
READ:  Cabaletta Bio Forges Ahead: A Strong Year Lays Groundwork for Groundbreaking Autoimmune Disease Therapies

Financial Results for the First Quarter Ended March 31, 2023

  • For the three months ended March 31, 2023, NRx Pharmaceuticals recorded $3.7 million of research and development expenses compared to $5.5 million for the year ended March 31, 2022. The decrease of $1.8 million is related primarily to a decrease of $1.8 million in clinical trials and development expenses related to ZYESAMI.
  • For the three months ended March 31, 2023, NRx Pharmaceuticals recorded $5.8 million of general and administrative expenses compared to $10.2 million for the three months ended March 31, 2022. The decrease of $4.4 million was primarily, related to a decrease of $3.9 million in legal, professional and accounting fees, $0.6 million in insurance expenses, $0.5 million in stock-based compensation expense, partially offset by $0.3 million in employee expenses and $0.2 million in consultant fees.
  • Assuming future debt payments can continue to be made in stock, the $16.5 million of cash and cash equivalents at the end of the first quarter of 2023 is expected to fund the Company’s operations through the expected delivery of data in the Company’s Phase 2b/3 trial. Additionally, the Company states it is evaluating operational efficiencies associated with the completion of manufacturing activities to extend this runway.

Additional information and details are available at https://ir.nrxpharma.com/.

For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News.